急性心肌梗死患者心室血栓与血小板体积和数量的相关性

目的分析急性心肌梗死(AMI)患者并发左心室血栓与平均血小板体积(MPV)和血小板计数(PLT)的相关性。方法回顾性分析2007年1月至2011年4月在阜外心血管病医院住院治疗的69例AMI并心室血栓形成患者,及138例与之年龄匹配(1∶2)的无心室血栓形成的AMI患者。比较两组患者入院时和入院后第6～8天两个时间点的MPV和PLT变化特点,以及分析MPV和PLT的相关性。结果两组患者入院时MPV差异无统计学意义[(10.3±1.0)fl比(10.3±0.8)fl,P=0.854],入院后第6～8天心室血栓组患者的MPV明显高于无心室血栓组[(11.1±1.7)fl比(10.7±0.7)fl,P=0.029]。入院时和入院后第6～8天PLT在两组间差异均无统计学意义(P=0.587、0.807)。入院后第6～8天患者MPV与PLT的关联表现为线性关系。结论 AMI患者MPV增大可能与心室血栓形成相关。     

Role of platelet inhibitor therapy in myocardial infarction

Summary Atherosclerotic plaque disruption is the predominant pathogenetic mechanism underlying the acute coronary syndromes. Plaque rupture leads to the exposure of collagen and vessel media, resulting in platelet and clotting activation, and occlusive thrombus formation. While drugs that interfere with platelet activation and function have been available for years, more powerful agents with novel mechanisms of action are being developed. Of the available platelet inhibitor drugs, only aspirin, sulfinpyrazone, and dipyridamole have undergone extensive clinical testing in patients with cardiovascular disease. More recently ticlopidine, a new and potent platelet inhibitor, has been successfully tested in patients with coronary and vascular disease.In acute myocardial infaction, aspirin significantly reduces cardiovascular mortality and reinfarction. Furthermore, the combination of aspirin and a thrombolytic agent produces maximal benefit. A role for heparin in the prevention of early mortality and reinfaction is emerging. This drug is effective for the prevention of left ventricular thrombosis in patients with anterior myocardial infarction.In the secondary prevention of reinfarction and cardiovascular mortality, available data support the use of a platelet inhibitor. Trials have shown that aspirin is as effective alone as in combination with dipyridamole, and is probably more effective than sulfinpyrazone. Long-term anticoagulant therapy also appears to be beneficial, but is associated with a high cost, need for extensive monitoring, and potential for hemorrhagic side effects.The role of aspirin in primary prevention is controversial. It may be indicated for patients at high risk for coronary disease in whom the benefit of therapy may outweigh the potential risk of cerebral bleeding.Coronary atherosclerotic plaque rupture, associated with thrombus formation, is fundamental to the development of acute myocardial infarction. Based on this concept, the role of antithrombotic therapy for the prevention or treatment of ischemic events in patients with coronary artery disease has stimulated enormous interest among clinicians and basic investigators. In this review we will examine: a) the pathogenesis of coronary thrombosis, b) the pharmacology of plateletinhibitor agents, and c) their role in the management of patients with acute myocardial infarction and in primary and secondary prevention of cardiovascular disease.Platelets interact with both the coagulation and fibrinolytic systems in the pathogenesis of thrombosis. While the purpose of this review is to discuss the role of platelets and platelet inhibitors in coronary disease, the use of anticoagulant or thrombolytic agents will be analyzed briefly when pertinent.     

Association of plasma miR-223 and platelet reactivity in patients with coronary artery disease on dual antiplatelet therapy: A preliminary report

Decreased plasma levels of microRNA-223 (miR-223), predominantly of platelet origin, were proposed as a surrogate marker of efficacy of antiplatelet therapy. However, higher on-treatment platelet reactivity was associated with lower plasma miR-223 in patients with coronary artery disease (CAD) on dual antiplatelet therapy (DAPT) including clopidogrel and aspirin. Our aim was to compare plasma miR-223 and platelet reactivity in CAD patients on DAPT with newer P2Y₁₂ antagonists vs. clopidogrel. We studied 21 men with CAD admitted to our centre owing to a non-ST-elevation acute coronary syndrome, and with an uncomplicated hospital course. From the day of admission, the patients were receiving either clopidogrel (n?=?11) or prasugrel/ticagrelor (n?=?10) in addition to aspirin. Before discharge, miR-223 expression in plasma was estimated by quantitative polymerase chain reaction using the comparative Ct method relative to miR-16 as an endogenous control. Multiple electrode aggregometry was used to assess platelet aggregation in response to adenosine diphosphate (ADP). ADP-induced platelet reactivity was decreased in the patients treated with prasugrel or ticagrelor compared with those on clopidogrel (mean?±?SD: 139?±?71 vs. 313?±?162 arbitrary units [AU]*min, p?=?0.006), due to a more potent antiplatelet activity of the novel P2Y₁₂ antagonists. Consequently, six out of seven patients in the lower tertile of the ADP-induced platelet aggregation were treated with the newer P2Y₁₂ blockers, whereas six out of seven patients in the upper tertile were on clopidogrel. Plasma miR-223 was elevated with decreasing platelet reactivity (Spearman’s rho?=?–0.52; p?=?0.015 for trend), being significantly higher in the lower tertile of the ADP-induced platelet aggregation (median [range]: 1.06 [0.25–2.31]) vs. the upper tertile (0.20 [0.13–2.30]) (p?=?0.04). In conclusion, our preliminary results argue against the notion of low plasma miR-223 as a marker of platelet responsiveness to DAPT. On the contrary, more potent platelet inhibition associated mainly with newer P2Y₁₂ antagonists appears to coincide with higher miR-223 relative to the subjects with attenuated responsiveness to DAPT.     

血小板膜糖蛋白I b的基因多态性与心肌梗塞发生关系的研究

目的　评价我国人群心肌梗塞的发生与血小板膜糖蛋白 (glycoprotein,GP)Ib基因多态性的关系。方法　采用病例对照研究 ,选择 10 0例确诊心肌梗塞的患者 (急性或陈旧性 )和 10 4例无心脏病史者作对照 ,用PCR SSP的方法进行血小板GPIbα链的基因多态性检测。结果　对照组无Met/Met纯合子 ,Thr/Met占 16.3 % ;心肌梗塞组Thr/Met Met/Met共占 3 0 % ,与对照组相比 ,P =0 .0 2 ,比数比 (oddsratio,OR)为 2 .2 (95 %可信区间 1.1～4 .3 )。在≤60岁发生心肌梗塞的患者Thr/Met Met/Met之和的频率(42 .2 % )更明显高于≤ 60岁的对照组 (14 .5 % ) (P =0 .0 0 2 ,OR =4 .3 ,95 %可信区间1.7～10 .8)。结论　血小板GPIb中Met等位基因与心肌梗塞之间呈显著的相关性 ,在≤60岁的人中 ,此种相关性更强。     

High post-clopidogrel platelet reactivity assessed by a point-of-care assay predicts long-term clinical outcomes in patients with ST-segment elevation myocardial infarction who underwent primary coronary stenting

Background

Recent studies have shown that post-clopidogrel high platelet reactivity (HPR), assessed by a point-of-care assay, is associated with a higher risk of adverse events after percutaneous coronary intervention (PCI). We assessed the clinical impact of HPR by the VerifyNow P2Y12 point-of-care assay in 181 patients with ST-segment elevation myocardial infarction (STEMI) who underwent primary PCI with drug-eluting stents (DES) at 3 hospitals.

Methods

The primary endpoint of the study was the 12-month major adverse cardiovascular events (MACE), which comprised cardiovascular death, nonfatal MI and ischemic stroke. All patients received a single loading dose of 600 mg clopidogrel and 300 mg aspirin followed by a daily maintenance dose of 75 mg clopidogrel and 100 mg aspirin.

Results

A P2Y12 reaction unit (PRU) ≥ 282 (AUC 0.719, 95% CI 0.588–0.851, p = 0.004, sensitivity 68.8%, specificity 73.8%) was the optimal cut-off value in predicting 12-month MACE by receiver operating characteristic curve analysis. Occurrence of MACE was significantly more frequent in patients with HPR (PRU ≥ 282) compared to patients without HPR (20.4% vs. 3.9%, HR 6.24, 95% CI 2.05–18.99, p = 0.001). By multivariate analysis, HPR (HR 3.84, 95% CI 1.17–12.58, p = 0.026) and elderly patients above 80 years of age (HR: 8.13, 95% CI 1.79–37.03, p = 0.007) were found to be the significant predictors of 12-month MACE. The MACE-free survival rate was significantly lower in patients with HPR compared to patients without HPR (p < 0.001).

Conclusion

HPR assessed by a point-of-care assay was able to predict 12-month MACE in patients with STEMI who underwent primary PCI with DES.     

替罗非班在急性心肌梗死患者急诊冠状动脉介入治疗无复流中的应用

目的评价冠状动脉内应用血小板膜糖蛋白(GP)Ⅱb/Ⅲa受体拮抗剂盐酸替罗非班,对急性心肌梗死患者梗死相关动脉行直接PCI后无复流现象的效果及对血小板活化功能的影响。方法选择330例急性心肌梗死患者直接行PCI出现无复流者48例,根据其用药情况分为硝酸甘油组(24例)和替罗非班组(24例)。两组均行冠状动脉造影,分别于术前和术后24 h检测血小板GPⅠb、GPⅡb/Ⅲa、GPⅢa。结果与用药前比较,两组术后均能改善冠状动脉血流,硝酸甘油组患者TIMI血流为(1.61±0.38)级vs(1.85±0.42)级(P<0.05),替罗非班组患者TIMI血流为(1.59±0.40)级vs(2.15±0.65)级(P<0.01)。替罗非班组患者术后24 h血小板GPⅠb、GPⅡh/Ⅲa、GPⅢa较术前明显降低(P<0.01)。结论冠状动脉内应用GPⅡb/Ⅲa受体拮抗剂替罗非班较安全。能更有效改善TIMI血流,并能在一定程度上抑制血小板活化。     

Validation of DAPT score for prolonged dual antiplatelet therapy in patients with acute myocardial infarction

IntroductionDual antiplatelet therapy (DAPT) after percutaneous coronary intervention (PCI) reduces the rate of ischemic events but increases bleeding risk. DAPT score helps identify patients who benefit from prolonged DAPT. Nevertheless, its accuracy in patients with acute myocardial infarction (AMI) remains uncertain. The aim of this study was to validate the use of DAPT score to predict ischemic and bleeding events in patients undergoing PCI for AMI and who received prolonged DAPT.Material and MethodsThis study included a cohort of patients with AMI who underwent PCI with stent placement and were treated with DAPT for more than 12 months.ResultsTwo hundred thirty subjects were included in the final analysis (age: 64 ± 12 years, 78% men, median follow-up: 31 months). Ischemic event (reinfarction or revascularization of target vessel or lesion) occurred in 17% and bleeding occurred in 5% of patients. DAPT score demonstrated modest prediction performance for ischemic events (C-statistic: 0.59, 95% confidence interval [CI]: 0.50-0.68, p<0.001) and a good prediction performance for bleeding events (C-statistic: 0.79, 95% CI: 0.66-0.92, p<0.001). Subjects with a DAPT score ≥2 had a greater risk of ischemic events (hazard risk [HR]: 3.1, 95% CI: 1.2-7.8, p = 0.019) and a lower risk of bleeding (HR: 0.23, 95% CI: 0.07-0.79, p = 0.019). Kaplan–Meier curves at 4 years showed that patients with a DAPT score ≥2 had lower ischemic-free survival rates (79% ± 4 vs. 90% ± 5, p = 0.0137) and higher bleeding-free survival rates (97% ± 2 vs. 90% ± 4, p = 0.0106).ConclusionsDAPT score is useful in patients with AMI, and a cut-off value of 2 identifies patients with a higher risk of ischemic events who might benefit from prolonged DAPT.     

Vitamin D levels and high-residual platelet reactivity in patients receiving dual antiplatelet therapy with clopidogrel or ticagrelor

Background: Suboptimal platelet inhibition still represents an important challenge, especially for patients undergoing percutaneous coronary interventions (PCIs). However, very few are known so far on the predictors of high-residual platelet reactivity (HRPR) despite antiplatelet strategies. Increasing attention has been paid in the last years to the role of vitamin D in atherothrombosis. Therefore, the aim of our study was to evaluate the impact of vitamin D levels on platelet function in patients treated with dual antiplatelet therapy (DAPT). Patients treated with DAPT (ASA and clopidogrel or ticagrelor) after a recent acute coronary syndrome (ACS) or elective PCI were scheduled for platelet function assessment at 30–90 days post-discharge. Platelet function was assessed by whole blood impedance aggregometry (Multiplate®-Roche Diagnostics AG), HRPR was considered for ASPI test values > 862 AU*min (for ASA) and adenosine diphosphate (ADP) test values ≥417 AU*min (for ADP-antagonists). Fasting samples were obtained for main chemistry parameters and vitamin D level assessment.

Our population is represented by 503 patients, who were divided according to vitamin D quartiles (≤9.1; 9.2–14.4; 14.5–21.7; >21.7 ng/ml). Lower vitamin D levels related with age (p = 0.04), diabetic status (p = 0.05), and previous coronary surgery (p = 0.007), therapy with beta-blockers and statins (p = 0.01 and p = 0.02). Vitamin D inversely related to the levels of total cholesterol (p = 0.01), triglycerides (p < 0.001), hemoglobin (p = 0.05), and HbA1c (p < 0.001). Significantly higher platelet reactivity was observed after platelet stimulation with ADP (p = 0.01), but not with other platelet activators. The prevalence of HRPR for ASA was low (1.2%) and not conditioned by Vitamin D levels (adjusted OR[95%CI] = 1.56[0.71–3.5], p = 0.27). HRPR with ADP-antagonists was observed in 26% of patients, and the rate increased with lower vitamin D quartiles (37.3% vs 22.2% vs 24.4% vs 20.2%, p = 0.005, adjusted OR[95%CI] = 1.23[1.02–1.49], p = 0.04).

An absolute increase in HRPR with lower vitamin D levels was similarly observed among patients receiving ticagrelor (adjusted OR[95% CI] = 1.40[0.95–2.06], p = 0.08), and those on clopidogrel (adjusted OR[95%CI] = 1.31[0.99–1.75], p = 0.06).

Thus, lower vitamin D levels are associated with higher platelet reactivity and impaired effectiveness of ADP-antagonists, while not influencing the effectiveness of ASA. Future studies will tell whether vitamin D supplementation can reduce platelet reactivity, overcoming the phenomenon of resistance to antiplatelet agents.     

STEMI患者服用替格瑞洛期间血清尿酸水平的变化及其对血小板反应性的影响初探

目的:比较行急诊经皮冠状动脉介入治疗（PCI）的ST段抬高型心肌梗死（STEMI）患者在服用替格瑞洛和氯吡格雷期间血清尿酸水平的变化,并初步探讨血清尿酸水平的变化对血小板反应性的影响。方法:选取2017年4月至2020年1月于阜外医院行急诊PCI存活出院且接受阿司匹林和替格瑞洛或氯吡格雷治疗的STEMI患者,分为替格瑞...     

平均血小板体积联合SYNTAX积分评估介入治疗非ST段抬高型心肌梗死患者远期预后的价值

【】 目的 探讨平均血小板体积(MPV)联合SYNTAX评分对急性非ST段抬高心肌梗死(NSTEMI)患者经皮冠状动脉介入(PCI)术后远期预后的评估价值。方法 选取2012年01月至2013年12月在南京医科大学附属淮安第一医院诊断NSTEMI并接受PCI治疗的患者158例,测定MPV水平及计算SYNTAX评分。随访12个月,根据随访结果分为心血管事件组和无心血管事件组,分析两组MPV水平、SYNTAX评分与心血管事件的关系。MPV联合SYNTAX评分预测主要不良心血管事件(MACE)效能用受试者工作特征(ROC)曲线下面积评价。结果 心血管事件组MPV水平、SYNTAX评分均高于无心血管事件组,差异具有统计学意义(P=0.025,P=0.021)。多因素cox回归分析显示,MPV和SYNTAX评分是远期发生心血管事件的独立预测因子。MPV联合SYNTAX评分预测PCI术后1年MACE受试者工作特征曲线下面积为0.713(95%CI：0.615～0.811,P=0.001)。将MPV、SYNTAX评分分别10.55fl、31分作为危险分层界值,绘制Kaplan-Meier生存曲线显示,高危组与低危组两组间发生心血管事件差异具有统计学意义(P=0.006)。结论 MPV与SYNTAX评分联合对急性非ST段抬高心肌梗死患者PCI术后远期预后评估有一定的价值。     

Comparison of peri-procedural platelet inhibition with prasugrel versus adjunctive cilostazol to dual anti-platelet therapy in patients with ST segment elevation myocardial infarction

BackgroundIt has been well known that the inhibition of platelet aggregation (IPA) by anti-platelet agents was important to reduce the thrombo-embolic events in patients with ST segment elevation myocardial infarction (STEMI). However, the peri-procedural IPA by anti-platelet agents was not well known.MethodsWe compared the peri-procedural IPA between prasugrel and adjunctive cilostazol to dual anti-platelet therapy (triple anti-platelet therapy; TAP) in patients with STEMI undergoing primary percutaneous coronary intervention (PCI). We prospectively randomized 70 consecutive clopidogrel-naive patients with STEMI planned PCI to either prasugrel [loading dose (LD) 60 mg; 37 patients] or TAP (LD aspirin 300 mg, clopidogrel 600 mg, and cilostazol 200 mg; 33 patients). Primary end points of the study were the platelet reactivity unit (PRU) or % inhibition by the VerifyNow P2Y₁₂ assay at pre-PCI and pre-discharge.ResultsThe drug loading to pre-PCI time was similar between prasugrel and TAP groups (25.4 ± 10.42 min vs. 25.5 ± 10.56 min, p = 0.957). PRU at pre-PCI was significantly lower in prasugrel than in TAP (269.1 ± 71.69 vs. 306.5 ± 48.67, p = 0.012). The lower PRU and greater % inhibition also observed in prasugrel than in TAP at pre-discharge (108.2 ± 60.51 vs. 238.1 ± 73.40; 63.6 ± 18.51% vs. 16.8 ± 17.91%, p < 0.001 respectively). No differences in in-hospital bleeding complications between the two groups were observed.ConclusionOur study demonstrates that prasugrel could produce a significantly greater peri-procedural as well as in-hospital IPA compared with TAP in patients with STEMI undergoing primary PCI.     

急性心肌梗塞溶栓后心律失常的意义及价值

作者对３０例急性心肌梗塞患者，经静脉应用尿激酶溶栓治疗，同时应用２４ｈ动态心电图监测。结果显示:前６ｈ内，１６例冠脉再通者，加速性室性自身节律发生率为８１．３％；１４例冠脉未通者，室性自身节律发生率为７．１％（Ｐ＜０．０１）。用其判断冠脉再通的敏感性为８１．３％，特异性为９２．９％，提示加速性室性自身节律是急性心肌梗塞患者溶栓后预测冠脉再通较可靠的无创指标。     

急性ST段抬高型心肌梗死PCI术后血小板CD40L及血小板指标临床相关性分析

【摘要】：目的：研究急性ST段抬高型心肌梗死PCI术后血小板CD40L及血小板指标之间相关性。方法：在我院接收的急性ST段抬高型心肌梗死患者中,选择2014年5月至2015年5月实施PCI术的患者58例作为研究对象,此组患者为观察组,选择同期健康体检人员53名作为对照组,对所有研究对象的血小板CD40L、血小板体积分布宽度(PDW)、血小板计数(PLT)、血小板压积(PCT)、血小板平均体积(MPV)、肌钙蛋白I(Tn-1)等指标进行测定,患者测定时间为手术前、后,对照组人员测定时间为参加研究时,比较两组研究对象各个指标水平,研究血小板CD40L及血小板指标的相关性。结果：观察组患者术前测得血小板CD40L(MFI)、Tn-1与对照组有显著差异,有统计学意义(P<0.05);观察组患者术前测得PCT、PLT、PDW、MPV与对照组差异较小,无具统计学意义(P>0.05);观察组患者术后测得血小板CD40L(MFI)、Tn-1、MPV、PDW均与对照组有显著差异,有统计学意义(P<0.05);观察组患者术后测得PCT、PLT与对照组差异较小,无统计学意义(P>0.05);观察组患者术后测得血小板CD40L(MFI)、Tn-1、MPV、PDW均与术前有较大差异,有统计学意义(P<0.05);观察组患者术后测得PCT、PLT与对照组差异较小,无统计学意义(P>0.05);STEMI患者行PCI术后,MPV、PDW与血小板CD40L呈正相关关系,P<0.05;Tn-1、PCT、PLT与血小板CD40L之间没有相关性,P>0.05。结论：血小板形态发生变化是急性ST段抬高型心肌梗死患者进行PCI术后血小板活化的特征,而血小板CD40L的表达受到血小板指标的影响,会产生炎症、凝血等情况,应予以重视。     

血小板受体糖蛋白Ⅲa基因与心肌梗塞关系的研究

目的探讨血小板受体糖蛋白（ＧＰＩＩａ）基因变异与心肌梗塞（ＭＩ）发病的关系。方法运用变性梯度凝胶电泳（ＤＧＧＥ）技术对４０例ＭＩ患者和相应数量健康人作对照行ＧＰＩＩａ基因全部外显子筛查。同时，以ＲＦＬＰ和ＡＳＯ技术检测８２例ＭＩ和６８例健康人对照的ＧＰＩＩａ基因ＰｌＡ多态性，并与５０例美国健康白种人比较。结果发现ＧＰＩＩａ基因外显子５中存在核苷酸静止突变；１５０例中国人的ＧＰＩＩａＰＩＡ多态基因型均为ＰｌＡ１／ＰｌＡ１，与美国白种人比较，差异有显著性。结论表明中国人群的血小板受体ＧＰＩＩａ基因与ＭＩ发病无相关性。     

Mean platelet volume predicts left descending artery occlusion in patients with non-ST-elevation myocardial infarction

Abstract

Platelets play an important role in atherothrombosis. As the most common site plaque occurs, left anterior descending artery (LAD) infarct location always associate with poor prognosis. We sought to assess whether mean platelet volume (MPV) could predict LAD infarct location and short-term clinical outcome. In this study, 190 consecutive patients with non-ST-elevation myocardial infarction (NSTEMI) were enrolled. Clinical, electrocardiography and laboratory characteristics were measured. All patients underwent coronary angiography examination and had definite culprit vessel during hospitalization. The results showed that MPV was smaller in patients with a LAD infarct location than that of left circumflex artery or right coronary artery (9.0?±?1.5 versus 9.8?±?1.6, p?<?0.001). Multivariate analysis also showed that MPV was the only independent factor to predict LAD infarct location [Odds ratio (OR)?=?0.65, 95% confidence interval (CI) 0.53–0.80, p?<?0.0001] in patients with NSTEMI. B-type natriuretic peptide and electrocardiography were unreliable predictive factors to locate culprit vessel. Receiver operating characteristic curve analysis showed MPV (area under the curve: 0.65, 95% CI 0.56–0.74, p?<?0.01) could reliably discriminate those patients with NSTEMI who had a major in-hospital event. Multivariate regression analyses also showed that MPV (OR?=?1.46, 95% CI 1.15–1.86, p?<?0.01) were predictors of major in-hospital events. In conclusion, MPV was the only factor independently associated with LAD infarct location in patients with non-ST-elevation myocardial infarction.     

冠心病介入术后性别对双联抗血小板治疗患者血小板反应性的影响

目的明确对于行经皮冠状动脉介入术(percutaneous coronary intervention,PCI)、服用双联抗血小板药物的冠心病患者血小板的反应性是否具有性别差异及对长期预后的影响。方法本研究纳入2013年1月至2013年12月于阜外医院行PCI且有术后12~72 h血栓弹力图检测结果的冠心病患者4606例,男3536例,女1070例。主要研究终点为2年主要不良心脑血管事件(major adverse cardiovascular and cerebrovascular events,MACCE:死亡、心肌梗死、靶血管或靶病变血运重建、脑卒中)及支架内血栓、大出血事件。结果通过对血栓弹力图的分析显示:男性、女性患者的花生四烯酸(arachidonic acid,AA)抑制率相似(81.0%±27.7%vs 79.7%±30.5%,P=0.178);男性二磷酸腺苷(adenosine diphosphate,ADP)抑制率高于女性(49.6%±31.2%vs 37.9%±31.2%,P<0.001);男性的二磷酸腺苷诱导的血小板纤维蛋白凝块强度(adenosine diphosphate-induced platelet-fibrin clot strength,MAADP)较女性更低[(32.6±17.1)mm vs(41.6±18.1)mm,P<0.001]。2年随访显示,男性、女性患者的MACCE发生率差异无显著性(8.5%vs 7.9%,P=0.377)。各单一主要终点事件中,男性患者死亡(1.2%vs 0.8%,P=0.045)及靶血管或靶病变血运重建(8.9%vs 6.4%,P=0.021)的发生率高于女性;其余单一主要终点事件无显著性差异。COX回归模型分析显示,MAADP并非MACCE及各单一主要终点事件的独立预测因素。结论2年随访显示,男性患者死亡及靶血管或靶病变血运重建的发生率高于女性,但MACCE发生率差异无显著性;MAADP并非是MACCE及各单一主要终点事件的独立预测因素。     

静脉溶栓后选择性PCI对急性心肌梗死患者远期预后的影响

目的探讨静脉溶栓后选择性经皮冠状动脉介入治疗(PCI)对急性心肌梗死(AMI)患者远期预后的影响.方法AMI患者114例,60例仅接受静脉溶栓者为药物组,54例静脉溶栓后平均(9.1±2.4)d行PCI者为手术组,分别于溶栓后及PCI后3、6、12个月随访主要心脏不良事件(MACE)发生情况.随访复查超声心动图,计算左室的整体室壁运动指数和左室射血分数.结果两组住院期间无死亡及心绞痛复发,手术组血管造影和操作成功率均为100%,无操作相关心肌梗死、急诊冠脉搭桥术(CABG).随访期间死亡率、因不稳定型心绞痛或心绞痛复发再次入院者手术组均显著少于药物组(P＜0.05),手术组总的临床终点事件发生率明显低于药物组(P＜0.01).结论 AMI患者静脉溶栓后选择性PCI能改善其远期预后.